Ask about this productRelated genes to: HER2 protein
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: HER2 protein
Related articles to: HER2 protein
- Clear cell renal cell carcinoma (ccRCC) is the predominant subtype of renal cancer with poor prognosis at advanced stages. The ErbB receptor family, including HER2, EGFR, and ErbB3, is implicated in tumor progression through membrane signaling and nuclear functions, but their roles in ccRCC remain incompletely understood. - Source: PubMed
Cortés María AliciaMarín Héctor MarceloCordo-Ruso RosaliaRott LuciaGiusiano Gustavo EmilioMerino Luis Antonio - Antibody-drug conjugates (ADCs) rely on specific recognition of tumor-associated membrane receptors to achieve targeted intracellular drug delivery, yet in situ characterization of their interaction dynamics remains limited. Here, we develop a single-cell plasmonic imaging platform to quantitatively resolve the interaction between the membrane human epidermal growth factor receptor 2 (HER2) and HER2-targeted therapeutics. This label-free approach enables continuous monitoring of the molecular interaction process, allowing real-time extraction of detailed binding kinetics. Using this platform, we systematically compare the binding behaviors of the HER2-targeting antibody trastuzumab (Herceptin) and clinically relevant ADCs (T-DM1 and T-DXd), revealing distinct kinetic signatures associated with the drug conjugation. Analysis across cell lines with different HER2 expressions reveals that increased receptor density does not necessarily enhance binding stability, suggesting a potential trade-off between receptor availability and effective interaction dynamics. To further evaluate the potential capability of tracking membrane-associated dynamics, polystyrene nanoparticle probes were employed to validate real-time imaging of endocytosis dynamics, distinguishing uptake behavior in live versus fixed cells.This work establishes cell-based plasmonic imaging as a quantitative and mechanistic approach for evaluating ADC-receptor interactions in situ, offering valuable insights for rational ADC design and precision therapeutic optimization. - Source: PubMed
Ding HaiyingLiu XiaoyinGuo BingxueQiu YuepingWu JingyuWang YunxiaoCui BaiqiFang LuoZhang Fenni - There is few research on which genes play an important role in tumors without lymph metastasis. This study aimed to identify candidate molecular alterations preferentially associated with N0-stage LUSC. - Source: PubMed
Publication date: 2026/08/31
Alipour MarzyehMoghanibashi MehdiNaeimi SirousMohamadynejad Parisa - Conditional activation of antisense oligonucleotides (ASOs) is a promising strategy for selective suppression of cancer cells without affecting normal cells. In this study, we developed a tripled-stranded ASO (tsASO) that is rendered inactive through complexation with two additional oligonucleotides. The key innovation is the use of partial overlap between the parent ASO and the biomarker sequence, combined with toehold-mediated strand displacement, enabling precise conditional activation. The tsASO effectively triggered RNase H-mediated degradation of DYNC1I2 and DARS1 RNAs exclusively in the presence of the ERBB2 sequence. In cell-free systems, the tsASO demonstrated high cleavage efficiency (up to 81%), comparable to the parent ASO efficiency, with minimal background activity in the absence of the biomarker sequence, validating the concept at the molecular level. However, in cells using lipid-based transfection, the tsASO exhibited nonspecific cytotoxicity that did not correlate with biomarker presence or target gene expression. Detailed analysis showed no clear support for known sequence-driven toxicity mechanisms (CpG/TLR9, G-quadruplexes) in the nonimmune cell lines, suggesting that the primary limitation is intracellular delivery rather than the tsASO design. Future work should focus on optimizing delivery platforms to achieve controlled cellular uptake and biomarker-dependent release, unlocking the therapeutic potential of this conditional gene silencing approach. - Source: PubMed
Drozd Valeriia STafran LiliaZaramenskih Nikolay VPanova Yulia AHussein ZainRybalko Daria SKolpashchikov Dmitry MEldeeb Ahmed A - Recent clinical trials have shown the usefulness of anti-HER2 (Human epidermal growth factor receptor 2) treatment in the newly described "HER2-low" subset of breast carcinoma, offering added treatment option to the once considered non-responders. This study aimed to identify this important new subset's demographic and pathological features in a Malaysian cohort. - Source: PubMed
Chiew S FLooi L MChang S WCheah P L